scorecardresearch

Roche gets USFDA approval for flu drug for children aged 5 and over

Xofluza is a single-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy against a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies, the company claims.

Roche, USFDA, Xofluza, influenza drug, health news, pharma news,
The FDA also approved Xofluza to prevent influenza in children aged five years and above the following contact with an infected person. (File)

Roche on Friday announced that it has received approval from the U.S. Food and Drugs Administration for its Xofluza drug to treat influenza in children aged five years and older.

According to Reuters’ report, the medicine has been approved to treat acute uncomplicated influenza in otherwise healthy children who have shown symptoms for no more than 48 hours.

The FDA also approved Xofluza to prevent influenza in children aged five years and above following contact with an infected person.

ALSO READ | Novo Nordisk and Roche partner together to enhance access to care for children with Type 1 diabetes in India

The company claims that the drug becomes the first single-dose oral influenza medicine approved in the United States for children in this age group. Moreover, Xofluza is already FDA-approved to treat influenza in people aged 12 and above.

Xofluza is a single-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy against a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies, the company claims.

Meanwhile, Xofluza is also approved for acute uncomplicated influenza in 27 other countries including Japan, Switzerland, Canada, Australia and South Korea, and is currently under review by the EMA.

ALSO READ | Roche’s experimental Alzheimer’s drug crenezumab fails to prevent cognitive decline in people

(With inputs from Reuters)

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In Pharma Healthcare